LegalView Announced its Newest Information Portal with Details of the Digitek Digoxin Heart Tablet Recall

Share Article

LegalView informed readers of its newest information portal detailing the U.S. Food and Drug Administration (FDA) ordered recall of the Digitek-brand digoxin heart tablets. The tablets had been recently discovered to have been manufactured containing twice the amount of active ingredient approved.

LegalView, the most comprehensive resource available for everything legal on the Web, announces the development of the Digitek digoxin information portal, which was created after the U.S. Food and Drug Administration (FDA) issued warnings of potential risks associated with improper manufacturing. The Digitek recall occurred en reports surfaced with information that some batches of Digitek digoxin contained double the appropriate amount of active ingredient. Digitek digoxin is a heart tablet that treats an array of heart rate irregularities such as atrial fibrillation (cardiac arrhythmia), atrial flutter (abnormal heart rhythm), abnormal heart rhythms and heart failure. Often, when these conditions are not treatable by other medications, a patient will receive a prescription for digoxin.

However, the excessive amount of active ingredient in the drug can cause digoxin toxicity, putting patients at risk for renal failure and potentially death. In many instances Digitek digoxin has also caused patients to suffer from digoxin side effects which can consist of vomiting, dizziness, nausea, low blood pressure and cardiac instability, according to the FDA. Individuals who have taken the botched batch of Digitek digoxin may be at risk for digitalis toxicity, which can result in death, and should contact a medical profession immediately. Patients are also advised to consult with a pharmaceutical lawyer for more information on developing a Digitek lawsuit to retrieve potential monetary compensation for the pain and suffering caused.

Additionally, LegalView offers information on other controversial prescription drugs including Chantix and Heparin. Chantix, a smoking cessation drug, was released to the market in May 2006 and had reportedly been prescribed to nearly 3 million Americans attempting to quit smoking. Reports began to surface in late 2007 about the Chantix side effects, which consisted of depression, erratic behavior, and suicidal thoughts and tendencies. Nearly 400 incidents of these side effects were reported to the FDA and approximately 38 suicides before the drug was recalled.

Finally, LegalView offers the most up-to-date news on the Heparin controversy for readers and victims of the Heparin recall. Heparin is a blood thinner injected into patients undergoing surgical procedures, usually heart-related procedures. It is used to prevent the development of blood clots, which are often deadly among surgical patients. A rash of allergic reactions began to appear in patients who had received Baxter's Heparin and it was soon discovered that the drug contained a contaminant that FDA officials allege had derived from a Chinese manufacturing plant. However, Chinese health officials continue to maintain their innocence and insist the drug's contamination occurred on U.S. soil. While victims continue to suffer from the after affects of the Heparin contamination, officials seemingly do nothing but point fingers. Patients who received this drug should speak with a pharmaceutical attorney at once to learn about developing a Heparin lawsuit.

About LegalView:

LegalView.com is a public service brought to you by Legal WebTV Network, LLC, a Limited Liability Corporation created by a group of the nation's most highly respected law firms: Anapol Schwartz; Brent Coon and Associates; Burg Simpson; Cohen, Placitella and Roth; James F. Humphreys and Associates; Lopez McHugh; and Thornton and Naumes. For more information on the accomplishments and track records of LegalView.com's superior sponsoring law firms and to get in touch with LegalView attorneys, visit LegalView at http://www.LegalView.com/.

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Katie Kelley

Alan Haburchak
Visit website